64
Participants
Start Date
February 28, 2007
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
Fludarabine
25 mg/m\^2 IV over 30 minutes daily for 3 days
Cyclophosphamide
250 mg/m\^2 IV over 30 minutes daily for 3 days
Rituximab
375 mg/m\^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m\^2 IV 30-minute infusion.
Bevacizumab
10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Genentech, Inc.
INDUSTRY
M.D. Anderson Cancer Center
OTHER